Many experimental studies have found that NF-κB may activate and mediate pulmonary inflammatory response in the pathogenesis of COVID-19, making the NF-κB signaling pathway one of the research hotspots in the treatment of COVID-19. Here, NFKB1 is linked to COVID-19.